Older adults:
In older adults, the recommended initial dose is 50-100 mg per day, divided into several dosages after meals, or as a single dose before sleep. In general, it is recommended to avoid administering single doses exceeding 100 mg. Do not exceed a daily dose of 300 mg.
Use in children and adolescents:
Trazodone is not recommended in children under 18 years of age due to the lack of sufficient safety and/or efficacy data.
Dosage for patients with kidney problems:
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor may monitor your renal function periodically.
Patients with liver problems:
If you have liver problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor may monitor your liver function periodically, as trazodone may damage your liver.
The tablets are scored to allow for a gradual increase in dose. If you split the tablet through the central score, you will get two halves of the tablet. Each half of the tablet contains 50 mg of trazodone.
If you take more Depraxthan you should:
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20 indicating the medication and the amount ingested. You can also go to the Emergency Service of the nearest hospital. Bring the packaging so that the doctor knows what you have taken.
The most frequent symptoms of overdose are: drowsiness, dizziness, nausea, and vomiting. In more severe cases, coma, convulsions, hyponatremia (low sodium concentration in the blood), hypotension (reduced blood pressure), tachycardia (rapid heart rate), and respiratory failure have been reported. Cardiac characteristics may include bradycardia (slow heart rate), prolonged QT interval, and Torsade de Pointes (a type of severe irregular heart rhythm). Symptoms may appear 24 hours or more after an overdose.The overdose of trazodone in combination with other antidepressants may cause serotonin syndrome.
If you forgot to take Deprax
Do not take a double dose to compensate for the missed doses. If you forget a dose, take it as soon as you remember. However, if it is almost time for the next dose, do not take the missed dose.
If you interrupt treatment with Deprax
Do not stop treatment with Depraxuntil your doctor tells you to. Your doctor will also help you to leave the treatment gradually. If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Depraxcan cause side effects, although not everyone will experience them.
Stop taking Depraxand see your doctor or go to the hospital immediately:
Talk to your doctor immediately if you notice the following side effects:
Other side effects:
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use:https://www.notificaram.es.
By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment..
Composition of Deprax
The active ingredient is trazodone. Each tablet contains 100 mg of trazodone hydrochloride, equivalent to 91.1 mg of trazodone.
The other components (excipients) are:
Appearance of the product and contents of the packaging
Deprax tablets are elongated, pink-orange in color, and scored on both sides.
Tablets are presented in aluminum blisters with PVC film and are available in boxes containing 30, 60, and 1,000 (clinical packaging) coated tablets.
Only some packaging sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
ANGELINI PHARMA ESPAÑA, S.L.
c/ Antonio Machado, 78-80
3rd floor, module A-Edificio Australia
08840 Viladecans, Barcelona (Spain)
Phone: 932 534 500
Responsible manufacturer
Alcalá Farma, S.L.
Avenida de Madrid, 82
28802 Alcalá de Henares (Spain)
Last review date of this leaflet: November 2023
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.